glp-1 asa guidelines for glp 1 Updated guidance for patients using GLP-1/GIP receptor agonists Holding GLP-1 Agonists Prior to
Description
Key Facts The Absolute Risk Expansion: The calculated increase in absolute risk is remarkably small, manifesting as approximately 3 to 4 additional cases of ischemic optic neuropathy per 10,000 patients treated with GLP-1 receptor agonists over a standard 18-month therapeutic window

Injection site reactions seem to be more commonly reported by people taking tirzepatide vs
Follow proper injection procedure

Dit zijn complexe stoffen
GLP-1 receptor agonists should be stopped in patients with acute kidney injury, and rehydration should be initiated

Other recognized adverse effects include injection site reactions, fatigue, headache, and dizziness